Bone markers in multiple myeloma

European Journal of Cancer

Volumn 42, Issue 11, 2006, Pages 1544-1553

  Heider, Ulrike ^a   Fleissner, Claudia ^a   Zavrski, Ivana ^a   Kaiser, Martin ^a   Hecht, Monica ^a   Jakob, Christian ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biochemical markers; Bone; DKK 1; ICTP; MIP 1; Multiple myeloma; NTx; Osteoblast; Osteocalcin; Osteoclast; Osteoprotegerin; RANKL; SDF 1

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; ISOENZYME; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR MARKER; WNT1 PROTEIN;

ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; BONE DESTRUCTION; BONE DISEASE; BONE REMODELING; BONE TURNOVER; CELL ACTIVATION; CELL ACTIVITY; CELL FUNCTION; DISEASE ACTIVITY; DISEASE MARKER; HEALING; HUMAN; INHIBITION KINETICS; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SERUM; SIGNAL TRANSDUCTION; SOLUBILITY; URINE; X RAY;

BIOLOGICAL MARKERS; BONE DISEASES; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MULTIPLE MYELOMA; OSTEOCLASTS; WNT PROTEINS;

EID: 33746338874     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.11.034     Document Type: Article

References (108)

1. Stead M., Brown J., Velikova G., et al. for the EORTC Study Group on Quality of Life. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with multiple myeloma. Brit J Haematol 104 (1999) 605-611
2. Melton III L.J., Kyle R.A., Achenbach S.J., Oberg A.L., and Rajkumar S.V. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20 (2005) 487-493
3. Bataille R., Chappard D., Marcelli C., et al. Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 76 (1990) 484-487
4. Kusumoto S., Jinnai I., Itoh K., et al. Magnetic resonance imaging patterns in patients with multiple myeloma. Br J Haematol 99 (1997) 649-655
5. Mariette X., Zagdanski A.M., Guermazi A., et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 104 (1999) 723-729
6. Valentin-Opran A., Charhon S.A., Meunier P.J., Edouard C.M., and Arlot M.E. Quantitative histology of myeloma-induced bone changes. Br J Haematol 52 (1982) 601-610
7. Yaccoby S., Wezeman M.J., Henderson A., et al. Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model. Cancer Res 64 (2004) 2016-2023
8. Mundy G.R., Raisz L.G., Cooper R.A., Schechter G.P., and Salmon S.E. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291 (1974) 1041-1046
9. Garrett I.R., Durie B.G., Nedwin G.E., et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317 (1987) 526-532
10. Choi S.J., Cruz J.C., Craig F., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96 (2000) 671-675
11. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., and Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumouur necrosis factors. Nature 319 (1986) 516-518
12. Lichtenstein A., Berenson J., Norman D., Chang M.P., and Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74 (1989) 1266-1273
13. Sati H.I., Greaves M., Apperley J.F., Russell R.G., and Croucher P.I. Expression of interleukin-1beta and tumouur necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol 104 (1999) 350-357
14. Nguyen L., Dewhirst F.E., Hauschka P.V., and Stashenko P. Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 10 (1991) 15-21
15. Cozzolino F., Torcia M., Aldinucci D., et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 74 (1989) 380-387
16. Kurihara N., Bertolini D., Suda T., Akiyama Y., and Roodman G.D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 144 (1990) 4226-4230
17. Zhang X.G., Klein B., and Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 174 (1989) 11-13
18. Iwasaki T., Hamano T., Ogata A., and Kakishita E. Clinical significance of interleukin-6 gene expression in the bone marrow of patients with multiple myeloma. Int J Haematol 70 (1999) 163-168
19. Alsina M., Boyce B., Devlin R.D., et al. Development of an in vivo model of human multiple myeloma bone disease. Blood 87 (1996) 1495-1501
20. Paul R., Bennett F., Calvetti J.A., et al. Molecular Cloning of a cDNA Encoding Interleukin 11, a Stromal Cell-Derived Lymphopoietic and Haematopoietic Cytokine. Proc Natl Acad Sci USA 87 (1990) 7512-7516
21. Ahlen J., Andersson S., Mukohyama H., et al. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone 31 (2002) 242-251
22. Lee J.W., Chung H.Y., Ehrlich L.A., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103 (2004) 2308-2315
23. Anderson D.M., Maraskovsky E., Billingsley W.L., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
24. Nakashima T., Kobayashi Y., Yamasaki S., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275 (2000) 768-775
25. Lum L., Wong B.R., Josien R., et al. Evidence for a role of a tumour necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 274 (1999) 13613-13618
26. Nagai M., Kyakumoto S., and Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 269 (2000) 532-536
27. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumour necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 (1999) 3540-3545
28. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
29. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
30. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., and Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250 (1998) 776-781
31. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
32. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
33. Khosla S. The OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
34. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., and Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15 (2000) 2-12
35. Hofbauer L.C., Neubauer A., and Heufelder A.E. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92 (2001) 460-470
36. Pearse R.N., Sordillo E.M., Yaccoby S., et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumour progression. Proc Natl Acad Sci USA 98 (2001) 11581-11586
37. Sezer O., Heider U., Zavrski I., Kuhne C.A., and Hofbauer L.C. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101 (2003) 2094-2098
38. Giuliani N., Bataille R., Mancini C., Lazzaretti M., and Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 (2001) 3527-3533
39. Roux S., Meignin V., Quillard J., et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117 (2002) 86-92
40. Okada T., Akikusa S., Okuno H., and Kodaka M. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis 20 (2003) 639-646
41. Croucher P.I., Shipman C.M., Lippitt J., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98 (2001) 3534-3540
42. Sezer O., Heider U., Jakob C., Eucker J., and Possinger K. Human bone marrow myeloma cells express RANKL. J Clin Oncol 20 (2002) 353-354
43. Sezer O., Heider U., Jakob C., et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99 (2002) 4646-4647
44. Farrugia A.N., Atkins G.J., To L.B., et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63 (2003) 5438-5445
45. Lai F.P., Cole-Sinclair M., Cheng W.J., et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 126 (2004) 192-201
46. Heider U., Zavrski I., Jakob C., et al. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. J Cancer Res Clin Oncol 130 (2004) 469-474
47. Oyajobi B.O., Traianedes K., Yoneda T., and Mundy G.R. Expression of Rank ligand (RANKL) by myeloma cells requires binding to bone marrow stromal cells via an a4b1-VCAM-1 interaction. Bone 23 (1998) S180 abstract
48. Heider U., Langelotz C., Jakob C., et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9 (2003) 1436-1440
49. Standal T., Seidel C., Hjertner O., et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100 (2002) 3002-3007
50. Zavrski I., Krebbel H., Wildemann B., et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 333 (2005) 200-205
51. Zavrski I., Jakob C., Schmid P., et al. Proteasome: An emerging target for cancer therapy. Anti-Cancer Drug 23 (2005) 475-481
52. Yaccoby S., Pearse R.N., Johnson C.L., Barlogie B., Choi Y., and Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116 (2002) 278-290
53. Body J.J., Greipp P., Coleman R.E., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
54. Cook D.N. The role of MIP-1 alpha in inflammation and haematopoiesis. J Leuk Biol 59 (1996) 61-66
55. Fuller K., Owens J.M., and Chambers T.J. Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J Immunol 154 (1995) 6065-6072
56. Abe M., Hiura K., Wilde J., et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100 (2002) 2195-2202
57. Kukita T., Nomiyama H., Ohmoto Y., et al. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of haematopoiesis and osteoclast recruitment. Lab Invest 76 (1997) 399-406
58. Uneda S., Hata H., Matsuno F., et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 120 (2003) 53-55
59. Hashimoto T., Abe M., Oshima T., et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125 (2004) 38-41
60. Choi S.J., Oba Y., Gazitt Y., et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108 (2001) 1833-1841
61. Oyajobi B.O., Franchin G., Williams P.J., et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumour burden in the murine 5TGM1 model of myeloma bone disease. Blood 102 (2003) 311-319
62. Lentzsch S., Gries M., Janz M., Bargou R., Dorken B., and Mapara M.Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signalling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101 (2003) 3568-3573
63. Su S., Mukaida N., Wang J., et al. Inhibition of Immature Erythroid Progenitor Cell Proliferation by Macrophage Inflammatory Protein-1α by Interacting Mainly With a C-C Chemokine Receptor, CCR1. Blood 90 (1997) 605-611
64. Yu X., Huang Y., Collin-Osdoby P., and Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18 (2003) 1404-1418
65. Zannettino A.C., Farrugia A.N., Kortesidis A., et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65 (2005) 1700-1709
66. Bataille R., Chappard D., Marcelli C., et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88 (1991) 62-66
67. Taube T., Beneton M.N., McCloskey E.V., Rogers S., Greaves M., and Kanis J.A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49 (1992) 192-198
68. Evans C.E., Galasko C.S., and Ward C. Does myeloma secrete an osteoblast inhibiting factor?. J Bone Joint Surg Br 71 (1989) 288-290
69. Evans C.E., Ward C., Rathour L., and Galasko C.B. Myeloma affects both the growth and function of human osteoblast-like cells. Clin Exp Metastasis 10 (1992) 33-38
70. Westendorf J.J., Kahler R.A., and Schroeder T.M. Wnt signalling in osteoblasts and bone diseases. Gene 341 (2004) 19-39
71. Gong Y., Slee R.B., Fukai N., et al. Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
72. Kawano Y., and Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116 (2003) 2627-2634
73. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
74. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor,sFRP-2. Blood 2005, Epub ahead of print.
75. Giuliani N, Colla S, Morandi F, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, Epub ahead of print.
76. Silvestris F., Cafforio P., Tucci M., Grinello D., and Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 122 (2003) 39-52
77. Silvestris F., Cafforio P., Calvani N., and Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 126 (2004) 475-486
78. Kitajima I., Nakajima T., Imamura T., et al. Induction of apoptosis in murine clonal osteoblasts expressed by human T-cell leukemia virus type I tax by NF-kappa B and TNF-alpha. J Bone Miner Res 11 (1996) 200-210
79. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., and Manolagas S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13 (1998) 793-802
80. Ehrlich L.A., Chung H.Y., Ghobrial I., et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106 (2005) 1407-1414
81. Barille S., Collette M., Bataille R., and Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 86 (1995) 3151-3159
82. Meilman E., Urivetzky M.M., and Rapoport C.M. Urinary hydroxyproline peptides. J Clin Invest 42 (1963) 40-50
83. Sassi M.L., Eriksen H., Risteli L., et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26 (2000) 367-373
84. Eriksen E.F., Charles P., Melsen F., Mosekilde L., Risteli L., and Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Mineral Res 8 (1993) 127-132
85. Pecherstorfer M., Seibel M.J., Woitge H.W., et al. Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90 (1997) 3743-3750
86. Abildgaard N., Glerup H., Rungby J., et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 64 (2000) 121-129
87. Carlson K., Larsson A., Simonsson B., Turesson I., Westin J., and Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62 (1999) 300-306
88. Jakob C., Zavrski I., Heider U., et al. Bone resorption parameters carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx) and deoxypyridinoline (Dpd) in MGUS and multiple myeloma. Eur J Haematol 69 (2002) 37-42
89. Jakob C., Zavrski I., Heider U., et al. Serum levels of carboxy-terminal telopeptide of type-I collagen (ICTP) are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 9 (2003) 3047-3051
90. Abildgaard N., Brixen K., Kristensen J.E., et al. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pretreatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 120 (2003) 235-242
91. Abildgaard N., Brixen K., Eriksen E.F., Kristensen J.E., Nielsen J.L., and Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 89 (2004) 567-577
92. Coleman R.E., Major P., Lipton A., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925-4935
93. Terpos E., de la Fuente J., Szydlo R., et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 106 (2003) 455-457
94. Corso A., Arcaini L., Mangiacavalli S., et al. Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients. Haematologica 86 (2001) 394-398
95. Fonseca R., Trendle M.C., Leong T., et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 109 (2000) 24-29
96. Terpos E., Palermos J., Tsionos K., et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 65 (2000) 331-336
97. Carlson K., Simonsson B., and Ljunghall S. Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism. Calcif Tissue Int 55 (1994) 408-411
98. Seidel C., Hjertner O., Abildgaard N., et al. Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98 (2001) 2269-2271
99. Lipton A., Ali S.M., Leitzel K., et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8 (2002) 2306-2310
100. Kyrtsonis M.C., Vassilakopoulos T.P., Siakantaris M.P., et al. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 72 (2004) 252-258
101. Corso A., Dovio A., Rusconi C., et al. Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia 18 (2004) 1555-1557
102. Depil S., Mathiot C., Leleu X., et al. Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. Br J Haematol 129 (2005) 706-707
103. Dovio A., Sartori M.L., and Angeli A. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 9 (2003) 2384-2385
104. Kraj M., Centkowski P., and Kruk B. Osteoprotegerin sRANKL serum levels in multiple myeloma patients. Haematol J 4 (2003) S157
105. Hofbauer L.C., and Schoppet M. Serum measurement of osteoprotegerin - clinical relevance and potential applications. Eur J Endocrinol 145 (2001) 681-683
106. Terpos E., Szydlo R., Apperley J.F., et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
107. Kraj M., Sokolowska U., Kruk B., and Centkowski P. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Haematologica 90 s1 (2005) 193 #1217
108. Terpos E., Politou M., Szydlo R., Goldman J.M., Apperley J.F., and Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 123 (2003) 106-109